TLDR Most patients experienced significant but reversible hair loss during treatment.
The study retrospectively evaluated alopecia in 470 patients treated with a paclitaxel and platinum combination for various gynecological cancers from 1993 to 2006. Patients received 6 cycles of chemotherapy with either paclitaxel and carboplatin or paclitaxel and cisplatin. Grade 3 alopecia was observed in 91.7% of patients, with no cases of grade 4 alopecia. The severity and frequency of alopecia were similar between the two chemotherapy combinations. Alopecia became more pronounced with additional chemotherapy cycles but was reversible after treatment concluded.
97 citations
,
September 2006 in “Pharmaceutical Research” No treatment fully prevents hair loss from chemotherapy yet.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
21 citations
,
August 2003 in “Seminars in oncology nursing” Nurses are crucial in managing chemotherapy side effects for ovarian cancer patients to improve their quality of life.
29 citations
,
August 2007 in “Annals of Oncology” Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
March 2018 in “International journal of basic and clinical pharmacology” Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.
